Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers
Journal of Clinical Pharmacy and Therapeutics, 07/10/09
Wen J et al. - The OATP 388A>G polymorphism causes significant alterations in the pharmacokinetics of pitavastatin in healthy Chinese volunteers and this may well be clinically significant.
Related Articles
Evaluation of Cynomolgus Monkey PXR, Primary Hepatocyte and In Vivo Pharmacokinetic Changes in Predicting Human CYP3A4 Induction
Drug Metabolism and Disposition, 10/21/09
Relevance Score: 89%
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects
British Journal of Clinical Pharmacology, 10/20/09
Relevance Score: 89%
Antiretroviral Adherence and Pharmacokinetics: Review of their Roles in Sustained Virologic Suppression
AIDS Patient Care and STDs, 10/05/09
Relevance Score: 89%
Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children
Acta Anaesthesiologica Scandinavica, 10/16/09
Relevance Score: 88%
Pharmacokinetic Outcomes of a Simplified, Weight-Based, Extended-Interval Gentamicin Dosing Protocol in Critically Ill Neonates
Pharmacotherapy, 10/27/09
Relevance Score: 87%
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Annals of Oncology, 12/04/09
Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients
Scandinavian Journal of Pain, 12/04/09
Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib
Clinical Pharmacology & Therapeutics, 12/03/09
Sponsor
Article Search
Sponsor


See Latest Articles


